FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Exosome Diagnostics has announced the placement of the world’s first system for exosome specific protein analysis, the Shahky system, within a large pharmaceutical company. The companies have near term plans to develop targeted assays containing clinically relevant biomarkers of interest, utilizing the Shahky system.
|
||||||||
By targeting disease specific exosomes and removing non-relevant proteins, the Shahky system is a powerful tool for drug development and patient stratification. The system enables rapid development of definitive disease specific exosomal protein biomarker signatures from any biofluid, including blood, cerebrospinal fluid, plasma, serum, urine, saliva, and ascites fluid.
“Exosome Dx is thrilled to continue expanding upon its strong partnerships within Pharma by giving them access to the newest of ExoDx’s novel technologies” stated Mario Morken, Head of Business Development at Exosome Diagnositcs. “By granting Pharma access to Shahky we aim to enable new discoveries and developments that will have therapeutic and/or diagnostic significance, building upon our foothold in the exoRNA and cfDNA space” Morken continued.
The commercial version of the Shahky, to be released in 2018 is on track to enable the following specs:
• NO UP-FRONT SAMPLE PREP IS REQUIRED – Sample In, Answer Out
• Ten microliters of biofluid input
• Label free detection
• Four-minute run time
• High sensitivity and specificity (1000x more sensitive than Western Blots and 100X more sensitive than ELISA)
• Small desktop footprint (12” x 16” x 18”) - optimal for clinical laboratories
• Quantitative disease specific protein analysis
“The Shahky system will allow pharmaceutical companies and researchers to leverage the full breadth of the Exosome Diagnostics’ solution, from liquid biopsy-based nucleic acid biomarkers to liquid-biopsy based protein biomarkers,” stated John Boyce, President and CEO of Exosome Diagnostics. “Exosome’s mantra has been to let the science dictate both the analyte and the measurement technology to derive the most predictive diagnostics tests. With the Shahky system, the company has now realized that vision,” Boyce continued.
About Exosome Diagnostics
Exosome Diagnostics is a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The company’s novel exosome-based technology platform, ExoLution™, and point of care instrument for protein capture and analysis, Shahky™, can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are diagnosed, treated and monitored. Visit www.exosomedx.com to learn more.
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c8df5ab1-2d1a-4967-951b-6201978b73b8
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/37133172-069f-4dc8-bbaf-0ebbaae4e5a3
Dan Baughman Exosome Diagnostics 248 613 2247 [email protected]
